【摘要】 目的探讨人工肝支持系统治疗对重型肝炎患者T淋巴细胞亚群水平的影响。方法选择2015年1月至2017年10月期间梅州市人民医院肝病科收治的98例重型肝炎患者,将接受人工肝(血浆置换)治疗的58例患者纳入观察组,常规治疗的40例患者纳入对照组,疗程14 d。比较两组患者治疗前后T淋巴细胞亚群(CD3+、CD4+、CD8+及CD4+/CD8+)的变化及临床疗效。结果观察组患者的治疗总有效率为79.31%,明显高于对照组的57.50%,差异有统计学意义(P<0.05);治疗后,观察组患者的CD3+、CD4+及CD4+/CD8+分别为(59.3±5.4)%、(36.5±4.7)%、(1.35±0.36),明显高于对照组的(53.8±4.7)%、(33.6±4.5)%、(1.26±0.36),差异均有统计学意义(P<0.05)。结论人工肝支持系统应用于重型肝炎的治疗,可以有效促进患者免疫功能的恢复,提高临床疗效,进而改善患者的预后。更多还原

【Abstract】 Objective To investigate the effect of artificial liver support system on the level of T lymphocyte subsets in patients with severe hepatitis. Methods A total of 98 patients with severe hepatitis treated in Department of Hepatology, Meizhou People’s Hospital from January 2015 to October 2017 were selected. Totally 58 patients who received artificial liver(plasma exchange) treatment were included into the observation group, and 40 patients who received routine treatment were included into the control group, with the course of treatment for 14 days. The changes and clinical efficacy of T lymphocyte subsets(CD3+, CD4+, CD8+and CD4+/CD8+) before and after treatment were compared between the two groups. Results The total effective rate of observation group was 79.31%, which was significantly higher than 57.50% of the control group(P<0.05). After treatment, the CD3+, CD4+, CD4+/CD8+in observation group respectively were(59.3±5.4)%,(36.5±4.7)%,(1.35±0.36), respectively, which were significantly higher than(53.8±4.7)%,(33.6±4.5)%,(1.26±0.36) in the control group(P<0.05). Conclusion The application of artificial liver support system in the treatment of severe hepatitis can effectively promote the recovery of immune function, improve the clinical efficacy, and improve the prognosis.更多还原